Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints

Preliminary top-line results of second Phase III study show highly significant decreases in pain and fatigue and improved daily function in fibromyalgia patients and confirm results from the first Phase III study PALO ALTO, Calif., and BRUSSELS, June 24 /PRNewswire-FirstCall/ -- press releas...

MADIT-CRT Trial Meets Primary Endpoint

Landmark trial shows Boston Scientific CRT-Ds slow the progression of heart failure in asymptomatic and mildly symptomatic patients NATICK, Mass., June 23 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) and the University of Rochester Medical Center today announced th...

VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease

Safety and Biologic Activity Data Reviewed in End of Phase 2a Meeting SAN FRANCISCO, June 11 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, annou...

Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US

CARLSBAD, Calif., May 17 /PRNewswire/ -- Essentialis Inc, a clinical stage pharmaceutical company, announced today that it met its primary endpoint of statistically significant triglyceride reduction in a 90-patient Phase 2b trial of DCCR in dyslipidemic patients. The study encompassed both patien...

Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome

- Favorable results for secondary endpoints support outcomes benefit HAYWARD, Calif., May 6 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that FRANCIS (Fewer Recurrent Acute coronary events ...

Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study

A Phase II Study Published in The Lancet of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI Major and Minor Bleeding and was Well Tolerated When Given With Standard Platelet Therapy KENILWORTH, N.J., March 12 /PRNewswire-FirstCall/ -- Results of a Schering-Plough Corporation (NYSE:...

Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant

-Company Provides Update on Cash Position- -Biologics License Application for Wrinkles/Nasolabial Folds Indication Expected To Be Filed Within Two Weeks- EXTON, Pa., March 5 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE ) announced today positive top-line efficacy results ...

Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

MOUNTAIN VIEW, Calif., Dec. 9 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) today announced positive results from its second Phase 3 clinical trial of AZ-004 (Staccato(R) loxapine). This Phase 3 clinical trial was conducted in patients with bipolar disorder experiencing...

TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia

LA JOLLA, Calif., Dec. 2 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as a treatment for xerostomia, or dry mouth, in patients with Sjogren's syndrome. NGX267 met the primary end...

Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease

KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that preladenant, its novel and selective adenosine2a receptor antagonist, met the primary endpoint in a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson...

NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect

PARIS, September 15 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced successful top-line results from the second phase 3 study for naproxcinod in 1020 patients with osteoarthritis of the knee (the 302 study). Both doses of naproxcinod (750 mg and 375 mg bid) met the t...

Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients

Conference Call Scheduled for Today - Tuesday, September 2, 2008 at 5:00 p.m. Eastern Time MOUNTAIN VIEW, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) today announced positive results from its first Phase 3 clinical trial of ...

Telik's Proteasome Inhibitor Program Meets a Preclinical Development Milestone

PALO ALTO, Calif., Aug. 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) announced today that its novel small molecule proteasome inhibitor program met a preclinical development milestone by demonstrating anticancer activity in preclinical models of human leukemia. The proteasome is a...

Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial

- Product appears safe with no dose-limiting toxicities - - Chemophase dose for pivotal trials successfully determined - - Halozyme to seek input from regulatory authorities in order to advance into pivotal clinical program in 2009 - SAN DIEGO, June 30 /PRNewswire-F...

Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture

XIAFLEX also Meets Primary Endpoint (p III Study Pharmacokinetic Study Demonstrates Lack of Systemic Exposure of XIAFLEX Serious Adverse Events Occurring at a 0.33% Rate per XIAFLEX injection Conference call scheduled for today, June 3, at 8:45 a.m. Eastern T...

Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids

Data Show TriLipix (ABT-335) in Combination with CRESTOR (rosuvastatin calcium) Improved LDL, HDL and Triglycerides and Had Reported Safety Consistent with Monotherapies SEATTLE, May 31 /PRNewswire-FirstCall/ -- New Phase III data showed that in patients with multiple lip...

Abbott's Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL

TriLipix in Combination With Statins Improved All Three Key Lipids and Had Reported Safety Consistent With TriLipix or Statin Monotherapies CHICAGO, March 31 /PRNewswire-FirstCall/ -- New data from two Phase III studies show that in patients with multiple lipid problems, Abbott's ABT-335 com...

Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache

Initial Analysis Shows Statistically Significant Pain Relief with the 2.5 and 5 mg Doses Compared to Placebo MOUNTAIN VIEW, Calif., March 3 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today positive top-line results from its 168 patient Ph...

Second Phase III Study of Avastin in 1st Line Metastatic Breast Cancer Meets its Primary Endpoint

- Results of This Trial Further Confirm the Benefit Avastin Brings to Patients With Breast Cancer. BASEL, Switzerland, Feb. 13 /PRNewswire/ -- Roche announced today that a phase III study in metastatic breast cancer investigating Avastin (bevacizumab) in combination with ...

ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study

SAN DIEGO, Nov. 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX ) today announced positive results from its marketing-enabling clinical study of ANX-530 (vinorelbine emulsion). Pharmacokinetic equivalence, the primary endpoint of the study, was observed between ANX-530 ...

A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females

REHOVOT, Israel, Nov. 6 /PRNewswire/ -- Meditor Pharmaceuticals Ltd. announced today that the primary end point and safety evaluation in the Phase II, Randomized Double Blind, Placebo-Controlled Dose-Escalating Study in Migraine patients was successfully completed. This event marks a major mil...

Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache

- Company Plans to Move Compound Forward into Phase III - - Conference Call Scheduled for Today at 9:00 A.M., Eastern Time - LA JOLLA, Calif., Oct. 22 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced that tezampanel met the primary endpoint in ...

Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults

Company Plans to File Supplemental New Drug Application with FDA in First Quarter 2008 SOUTH SAN FRANCISCO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV ) today announced positive top-line results from its pivotal Phase 3 trial. The multi-c...

ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

NEW YORK, Sept. 11 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated (Nasdaq: IMCL ) and Bristol-Myers Squibb Company (NYSE: BMY ) today announced that a Phase III study of ERBITUX(R) (Cetuximab) in combination with platinum-based chemotherapy (vinorelbine plus cisplatin) met its primar...

Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint

Estimates Peak Worldwide Transplant Opportunity of Over $400 Million Annually CAMBRIDGE, Mass., Aug. 2 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ ) today announced that its second phase 3 trial of Mozobil(TM) (plerixafor) has successfully met its pr...

Replidyne Phase II Pediatric Trial Meets Primary Objective

LOUISVILLE, Colo., March 06, 2007 /PRNewswire-FirstCall/ -- Replidyne, Inc. announced today that it has completed its Phase II clinical trial using faropenem medoxomil (faropenem) in pediatric patients with acute otitis media (AOM), a common infection of the middle ear. Initial analyses of the stu...

Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation

Initial Analysis Shows Statistically Significant Changes in Agitation Levels With 10 mg AZ-004 PALO ALTO, Calif., March 26, 2007 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. today announced positive initial results from its Phase IIa clinical trial of AZ-004 (Staccato(R) loxapine) in sch...

DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - Dyax Corp. (Nasdaq:DYAX) announced today positive topline results from its Phase 3, placebo-controlled trial, EDEMA3, for its lead product candidate DX-88 (ecallantide), for hereditary angioedema (HAE). A webcast presentation of the EDEMA3 data is s...

SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial

-- Data Presented at Annual Meeting of the American Society of Clinical Oncology -- SAN MATEO, Calif. -- June 4, 2007 -- SciClone Pharmaceuticals, Inc. (Nasdaq:SCLN) and Sigma-Tau S.p.A today announced that SciClone's lead product candidate thymalfasin (ZADAXIN(r), thymosin alpha 1) achieved its...

Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 6, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Study 102, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread (tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment for chronic hep...

Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint

DUBLIN, Ohio--(BUSINESS WIRE)--Jun 20, 2007 - Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced positive preliminary results from a multicenter Phase 2 clinical study of its lead clinical candidate,...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Study 103, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment for chronic...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--June 25, 2007--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Study 103, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment for chroni...

ENDEAVOR IV Clinical Trial Meets Primary Endpoint

MINNEAPOLIS--(BUSINESS WIRE)--Jul 2, 2007 - Medtronic, Inc., (NYSE:MDT) today announced that a review of data from the ENDEAVOR IV Clinical Trial indicates that the trial has met its primary, non-inferiority endpoint. The ENDEAVOR IV Clinical Trial is a randomized, single-blind trial evaluating th...

Online H1N1 Management: FairChoice Helps Schools Respond to Infectious Disease on Campus

...ollment. "In an emergency, campus health officers need to know in real-time whether their message is getting out to students. FairChoice Health meets students where they are -- online. Our automated notification and tracking service will increase student awareness of the risks of infectious disease ...

Teeth and Gums Also Benefit from the Healing Power of Aloe Vera

...ria, MS, DDS, MAGD, MA. "If they are interested in a more alternative approach to oral hygiene, they should speak with their dentist to ensure that it meets the standards of organized dentistry, too." Editor's Note: A copy of the study, "Comparative evaluation of the antimicrobial efficacy of aloe...

International Journal of Occupational and Environmental Health Features Discovery of Asbestos-Related Pain Origin from Scientists at the Karmanos Cancer Institute in Detroit

...based on the CT findings, the physical examination, pulmonary function studies, epidemiology and history of the patient's intractable pleural pain meets the criteria for diagnosis of asbestosis. Combined with the known science of taconite dust, a link between the mine where the patient's father worked ...

Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes

...ar that not all laboratories can reproduce positive results. In those laboratories, PGS should be considered experimental." To find a clinic that meets the protocol as published in Fertility and Sterility, requirements for preimplantation genetic diagnosis, contact client services at Reprogenetics, ...

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients

... - Fifth International Phase III ACTEMRA Study meets its Primary Endpoints - NUTLEY, N.J., May 25 /PRNewswire/ -- Roche today announced that two-year data from the LITHE (Toci LI zumab Safety an...

invivodata Certified to Deliver EXACT in COPD Trials

...eidy, senior vice president of scientific affairs for UBC and Principal Investigator of the EXACT-PRO Initiative. "We have found their e-diary device meets the needs of the EXACT and is ready for use in international trials." Licensing agreements to use the EXACT are obtained directly from United Bi...